MedTrace Logo

A Study of ALPN-303 in Adult Healthy Volunteers

NCT05034484 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2023-05-09

No results posted yet for this study

Summary

This study is to assess the safety, tolerability, pharmacokinetics (the amount of drug in the blood), pharmacodynamics (how the drug effects the body) and immunogenicity (how the drug effects the immune system) of a single dose of an investigational drug called ALPN-303. Multiple dose levels will be tested.

Conditions

  • Healthy Volunteers

Interventions

DRUG

ALPN-303

Multiple dose levels will be evaluated.

DRUG

Placebo

Placebo will be administered

Sponsors & Collaborators

  • Alpine Immune Sciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Stanford Peng, MD PhD · Alpine Immune Sciences, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-15
Primary Completion
2023-02-27
Completion
2023-02-27

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05034484 on ClinicalTrials.gov